Natera, Inc. Common Stock (NTRA) Price and Market Data

Natera, Inc. is a diagnostics and research company focused on proprietary molecular and bioinformatics technologies. Its main offerings include the Panorama Non-Invasive Prenatal Test (NIPT), which screens for fetal chromosomal abnormalities, including in twin pregnancies, typically through a maternal blood draw; Horizon Carrier Screening (HCS), which identifies carrier status for numerous serious genetic diseases that may be passed to children; the Signatera molecular residual disease (MRD) test, designed to detect circulating tumor DNA in patients previously diagnosed with cancer to evaluate residual disease and monitor recurrence; and Prospera, which is used to assess organ transplant rejection.